Evidence map›Paper›PMID 12970090›Full record

ArticleBritish journal of pharmacology2003

CL/RAMP2 and CL/RAMP3 produce pharmacologically distinct adrenomedullin receptors: a comparison of effects of adrenomedullin22-52, CGRP8-37 and BIBN4096BS.

D L Hay, S G Howitt, A C Conner, M Schindler, D M Smith, D R Poyner

Open access · greenAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of pharmacology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 131 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Precursor proadrenomedullin influences cardiomyocyte survival and local inflammation related to myocardial infarction.Proceedings of the National Academy of Sciences of the United States of America · 2018
    Article
  13. hThe Journal of experimental medicine · 2018
    Article
  14. Article
  15. Article
  16. G protein-coupled receptors: what a difference a 'partner' makes.International journal of molecular sciences · 2014
    Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 3 countries.

D L HayPharmaceutical Sciences Research Institute, Aston University, Birmingham B4 7ET, UK.
S G Howitt
A C Conner
M Schindler
D M Smith
D R Poyner
Aston University · GBAstraZeneca (United Kingdom) · GBBoehringer Ingelheim (Germany) · DEUniversity of Auckland · NZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adrenomedullin (AM) has two known receptors formed by the calcitonin receptor-like receptor (CL) and receptor activity-modifying protein (RAMP) 2 or 3: we report the effects of the antagonist fragments of human AM and CGRP (AM22-52 and CGRP8-37) in inhibiting AM at human (h), rat (r) and mixed species CL/RAMP2 and CL/RAMP3 receptors transiently expressed in Cos 7 cells or endogenously expressed as rCL/rRAMP2 complexes by Rat 2 and L6 cells. AM22-52 (10 microM) antagonised AM at all CL/RAMP2 complexes (apparent pA2 values: 7.34+/-0.14 (hCL/hRAMP2), 7.28+/-0.06 (Rat 2), 7.00+/-0.05 (L6), 6.25+/-0.17 (rCL/hRAMP2)). CGRP8-37 (10 microM) resembled AM22-52 except on the rCL/hRAMP2 complex, where it did not antagonise AM (apparent pA2 values: 7.04+/-0.13 (hCL/hRAMP2), 6.72+/-0.06 (Rat2), 7.03+/-0.12 (L6)). On CL/RAMP3 receptors, 10 microM CGRP8-37 was an effective antagonist at all combinations (apparent pA2 values: 6.96+/-0.08 (hCL/hRAMP3), 6.18+/-0.18 (rCL/rRAMP3), 6.48+/-0.20 (rCL/hRAMP3)). However, 10 microM AM22-52 only antagonised AM at the hCL/hRAMP3 receptor (apparent pA2 6.73+/-0.14). BIBN4096BS (10 microM) did not antagonise AM at any of the receptors. Where investigated (all-rat and rat/human combinations), the agonist potency order on the CL/RAMP3 receptor was AM approximately betaCGRP>alphaCGRP. rRAMP3 showed three apparent polymorphisms, none of which altered its coding sequence. This study shows that on CL/RAMP complexes, AM22-52 has significant selectivity for the CL/RAMP2 combination over the CL/RAMP3 combination. On the mixed species receptor, CGRP8-37 showed the opposite selectivity. Thus, depending on the species, it is possible to discriminate pharmacologically between CL/RAMP2 and CL/RAMP3 AM receptors.

Indexed as

AdrenomedullinAnimalsCalcitonin Gene-Related PeptideCalcitonin Receptor-Like ProteinChlorocebus aethiopsCOS CellsCyclic AMPDose-Response Relationship, DrugHumansIntracellular Signaling Peptides and ProteinsMembrane ProteinsPeptide FragmentsPeptidesPiperazinesQuinazolinesRatsAdrenomedullinadrenomedullin (22-52)Calcitonin Gene-Related Peptidecalcitonin gene-related peptide (8-37)Calcitonin Receptor-Like ProteinCALCRL protein, humanCalcrl protein, ratCyclic AMPIntracellular Signaling Peptides and ProteinsMembrane ProteinsolcegepantPeptide FragmentsPeptidesPiperazinesQuinazolinesRAMP2 protein, humanRamp2 protein, ratRAMP3 protein, humanRamp3 protein, ratReceptor Activity-Modifying Protein 2Receptor Activity-Modifying Protein 3Receptor Activity-Modifying ProteinsReceptors, AdrenomedullinReceptors, CalcitoninReceptors, Peptide

Identifiers

PMID12970090
PMCPMC1574059
OpenAlexW2013111477

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.